Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

89.43EUR
11:35am EDT
Price Change (% chg)

€2.08 (+2.38%)
Prev Close
€84.61
Open
€87.83
Day's High
€89.96
Day's Low
€87.74
Volume
2,688,204
Avg. Vol
2,080,847
52-wk High
€89.96
52-wk Low
€60.41

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German management holding company with core competencies in the field of health care, nutrition and high-tech materials. It's business operations are organized into three subgroups: HealthCare, involved in the research, development and manufacture of health products for people and animals, CropScience, engaged in... (more)

Overall

Beta: 0.78
Market Cap (Mil.): €72,233.89
Shares Outstanding (Mil.): 826.95
Dividend: 1.90
Yield (%): 2.18

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 28.26 37.93 37.76
EPS (TTM): 3.09 -- --
ROI: 6.59 19.48 18.76
ROE: 12.89 20.17 19.59
Search Stocks

European shares kept buoyant by data, earnings

LONDON, July 31 - European equities rose on Wednesday, kept buoyant by robust data out of the United States and Europe as well as strong earnings releases from major companies.

31 Jul 2013

UPDATE 1-Bayer warns outlook seems ambitious as plastics weaken

* Shares indicated 2 pct lower (Adds details on new drugs, MaterialScience unit)

31 Jul 2013

EU Commission clears way for Bayer acne pill sales in France

BRUSSELS, July 30 - The European Commission confirmed on Tuesday that the Bayer acne pill Diane 35 was safe for use, a seal of approval which will oblige France to allow sales of the product.

30 Jul 2013

Analysis: Bayer immune to pharma's breakup bug?

FRANKFURT - Investors banking on Bayer to embrace a trend in the pharma sector to split off non-core units may be too far ahead of the curve.

29 Jul 2013

Bayer starts clinical of drug for children with haemophilia

FRANKFURT, July 8 - Bayer AG said it had started a late stage clinical trial of its drug BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children with severe haemophilia A, it said in a statement on Monday. (Reporting by Jonathan Gould; Editing by Christoph Steitz)

08 Jul 2013

BRIEF-Bayer's Nexavar submitted to EMA, FDA for thyroid cancer use

FRANKFURT, July 1 - Bayer AG : * Says sorafenib (nexavar) submitted to the ema and FDA for use in thyroid

01 Jul 2013

Bayer cancer drug recommended in EU

LONDON, June xx - Experts at the European Medicines Agency have recommended approval of Bayer's drug Stivarga for the treatment of metastatic colorectal cancer.

28 Jun 2013

Bayer rival Boehringer seeks wider use of anti-clotting pill

FRANKFURT - Boehringer Ingelheim has asked European regulators to approve a wider use of its anti-blood-clotting pill Pradaxa to include the treatment of deep vein thrombosis and pulmonary embolisms.

24 Jun 2013

Europe shares dip as Chinese data hits miners

PARIS, June 10 - European stocks ended slightly lower on Monday as China's unexpectedly weak imports data prompted investors to dump cyclical miners and pick up defensive companies such as Deutsche Telekom and Bayer .

10 Jun 2013

Bayer say VEGF Trap-Eye shows promise as mCNV treatment

FRANKFURT, June 6 - Bayer said on Thursday its drug VEGF Trap-Eye had demonstrated to improve visual acuity in a late-stage trial on patients suffering from myopic choroidal neovascularization (mCNV).

06 Jun 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$472.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks